| 摘要 |
A method whereby in an individual showing evidence of dysregulation of elements of the Polymorphic Metabolic Dysfunction (PMD), which is defined as the dysregulation of the metabolism of insulin, glucocorticoids, leptin, resistin and peroxisome proliferator-activated receptor gamma (PPARgamma), this regulation is improved when that person receives an appropriate administration of (-)-hydroxycitric acid. The potassium salt of (-)-hydroxycitric acid is a preferred form of the compound, followed by the sodium salt, then by the amide and other salt forms and derivatives of the acid. The regulation of Polymorphic Metabolic Dysfunction over any given period of time may be improved with a controlled release form of (-)-hydroxycitric acid. Controlled release can be used to provide a sustained and modulated amount of the active to the body as desired and therefore to regulate the use of the compound as Polymorphic Metabolic Dysfunction regulative agent.
|
